TENXのチャート
TENXの企業情報
| symbol | TENx |
|---|---|
| 会社名 | Tenax Therapeutics Inc （テナックス・セラピュ―ティックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Commercial Physical_Biological Resarch |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 テナックス・セラピュティクス（Tenax Therapeutics Inc） (旧名：Oxygen Biotherapeutics Inc)は特定の標的組織への酸素運搬を中心としたバイオテクノロジー製品の開発事業に従事する。同社は全身性パーフルオロカーボン（PFC）製品「Oxycyte」を開発している。それ以外、同社は個人医療、局部創傷治癒、局部適応症などに使用されるパーフルオロカーボンをベースとする一連の酸素担体を開発した。同社はまた、「Dermacyte」及び「Wundecyte」という局所製品の開発に注力する計画がある。同社は「Vitavent」という肺疾患を治療する開発中の酸素交換液体がある。同社はまた、皮下液体に含まれるグルコースレベルを測定する酵素プロセスを利用するバイオセンサ移植組織片製品に対する権利を有する。同社は、付加的な臨床研究プロトコールを開発し、座瘡の治療、酒さ、かゆみ、乾癬、および皮膚炎などの局所の徴候のための概念実証研究を実施する予定がある。 テナックス・セラピュ―ティックスは、米国の製薬会社。心拍出量症候群を発症する危険性の心臓手術患者における罹患率および死亡率の低減に使用するレボシメンダンを含むクリティカル・ケア市場向けの医薬製品の開発・商品化を展開する。製品は、｢Oxycyte｣、｢Dermacyte｣、｢Wundecyte｣がある。 Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). Tenax plans to advance a delayed release oral formulation of imatinib, designed to avoid the gastric irritation, into a single pivotal trial pursuant to the 505(b)(2) pathway. |
| 本社所在地 | ONE Copley Parkway Suite 490 Morrisville NC 27560 USA |
| 代表者氏名 | Ronald R. Blanck ロナルド・R・ブランク |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 919-806-4414 |
| 設立年月日 | 24593 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 11人 |
| url | www.tenaxthera.com |
| nasdaq_url | https://www.nasdaq.com/symbol/tenx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -5.79296 |
| 終値（lastsale） | 5.24 |
| 時価総額（marketcap） | 7679199.04 |
| 時価総額 | 時価総額（百万ドル） 7.47403 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1.06688 |
| 当期純利益 | 当期純利益（百万ドル） -5.62933 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Tenax Therapeutics Inc revenues was not reported. Net loss decreased 51% to $3.1M. Lower net loss reflects Other Research and development decrease of 91% to $296K (expense) Personnel costs decrease of 17% to $1.6M (expense) Legal and professional fees decrease of 19% to $845K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$4.44 to -$2.12. |
TENXのテクニカル分析
TENXのニュース
Tenax Therapeutics GAAP EPS of -$1.58 misses by $1.51 (NASDAQ:TENX) 2022/03/31 13:26:34 Seeking Alpha
Tenax Therapeutics press release (TENX): FY GAAP EPS of -$1.58 misses by $1.51.Cash, cash equivalents and marketable securities totaled $5.6 million as of December 31, 2021, compared…
Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update 2022/03/31 12:30:00 Business Wire
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the year ended December 31, 2021 and provided a business update. “With the advancement of our proprietary formulation of oral imatinib, TNX-201, we believe Tenax is poised to fundamentally change the treat
Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions 2022/03/30 21:00:00 Kwhen Finance
Tenax Therapeutics Inc Shares Fall 2.3% Below Previous 52-Week Low - Market Mover 2022/01/14 04:40:18 Kwhen Finance
Tenax Therapeutics Inc (TENX) shares closed 2.3% lower than its previous 52 week low, giving the company a market cap of $20M. The stock is currently down 20.7% year-to-date, down 54.7% over the past 12 months, and down 98.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 23.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 134.3% The company's stock price performance over the past 12 months lags the peer average by 1476.5%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Tenax Therapeutics nabs new U.S. patent for the subcutaneous use of levosimendan 2022/01/12 13:36:19 Seeking Alpha
Tenax Therapeutics (TENX) announces that the USPTO has granted a patent for the companys subcutaneous formulation of levosimendan, TNX-102, which is currently being developed for
Tenax Therapeutics Inc Shares Fall 2.3% Below Previous 52-Week Low - Market Mover 2022/01/14 04:40:18 Kwhen Finance
Tenax Therapeutics Inc (TENX) shares closed 2.3% lower than its previous 52 week low, giving the company a market cap of $20M. The stock is currently down 20.7% year-to-date, down 54.7% over the past 12 months, and down 98.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 23.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 134.3% The company's stock price performance over the past 12 months lags the peer average by 1476.5%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Tenax Therapeutics nabs new U.S. patent for the subcutaneous use of levosimendan 2022/01/12 13:36:19 Seeking Alpha
Tenax Therapeutics (TENX) announces that the USPTO has granted a patent for the companys subcutaneous formulation of levosimendan, TNX-102, which is currently being developed for
Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102) 2022/01/12 13:30:00 Benzinga
Provides Broad Coverage for Use of TNX-102 for the Treatment of Human Subjects with Any Health Condition Patent Term to 2039, Exclusive of Any Possible Extensions MORRISVILLE, N.C., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ: TENX ), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the company''s subcutaneous formulation of levosimendan, TNX-102, which is currently being developed for the treatment of pulmonary hypertension associated with left heart failure (PH-HFpEF). On January 4, 2022, Tenax Therapeutics was issued US Pat. No. 11,213,524, entitled PHARMACEUTICAL COMPOSITIONS FOR SUBCUTANEOUS ADMINISTRATION OF LEVOSIMENDAN , which is directed towards the use of levosimendan via subcutaneous administration for treating a subject having a health condition of any kind, such as heart failure, pulmonary hypertension including PH-HFpEF, chronic kidney disease, stroke, or other health conditions.
Tenax Therapeutics Inc Shares Close the Day 11.6% Lower - Daily Wrap 2022/01/07 11:13:37 Kwhen Finance
Tenax Therapeutics Inc (TENX) shares closed today 11.6% lower than it did at the end of yesterday. The stock is currently down 15.4% year-to-date, down 50.8% over the past 12 months, and down 98.1% over the past five years. Today, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 0.1%. Trading Activity Shares traded as high as $1.46 and as low as $0.84 this week.Shares closed 76.1% below its 52-week high and 5.2% above its 52-week low.Trading volume this week was 272.1% higher than the 10-day average and 849.8% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.
Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 345.3% The company's stock price performance over the past 12 months lags the peer average by -1042.4%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Tenax Therapeutics, Inc. (NASDAQ:TENX) Expected to Announce Earnings of -$0.16 Per Share 2021/12/20 06:12:44 Dakota Financial News
Wall Street analysts expect Tenax Therapeutics, Inc. (NASDAQ:TENX) to report earnings per share (EPS) of ($0.16) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Tenax Therapeutics earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.15). Tenax Therapeutics reported earnings of ($0.60) per share during the same []
Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH) 2021/10/06 12:30:00 Business Wire
Tenax Therapeutics, Inc. today announced that the FDA has reviewed and cleared its Investigational New Drug (IND) application for imatinib.
Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF) 2021/08/12 12:00:00 Business Wire
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces article in Journal of Cardiac Failure identifying novel mechanism of action in Phase 2 HELP Study
Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) 2021/08/05 12:00:00 Business Wire
MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces Levosimendan in PH-HFpEF webinar on Aug. 16th at 10 am, with Drs. Daniel Burkhoff & Stuart Rich.
Tenax Therapeutics pulls in $10M two weeks after naming new CEO | WRAL TechWire 2021/07/22 17:36:07 WRAL TechWire
MORRISVILLE - Two weeks after naming a new CEO, the publicly-traded Tenax Therapeutics, Inc. (Nasdaq: TENX) has raised nearly $10 million from an undisclosed
Traumatic Brain Injuries Treatment Market 2021 Industry Outlook, Comprehensive Insights and Forecast 2026 | Neuren Pharmaceuticals, TEVA Pharmaceutical Industries, Grace Laboratories, NeuroScience Pharmaceuticals, Tenax Therapeutics 2021/07/14 11:17:37 Tramways Monthly
Report Hive Research Market Reports has recently published a market research report titled, Traumatic Brain Injuries Treatment Market Size, Status and Forecast 2021-2026. Analysts have used primary and secondary research methodologies to determine the path of the market. The data includes historic and forecast values for a well-rounded understanding. It is a phenomenal compilation []